| |
OR
|
95% CI
|
|---|
|
Age
|
1.04
|
0.98–1.11
|
|
Male
|
0.59
|
0.17–2.14
|
|
Disease duration
|
0.93
|
0.88–0.99*
|
|
TNFi type (ref: infliximab)
|
0.46
|
0.15–1.39
|
|
csDMARD (ref: use of any csDMARD)
|
3.82
|
1.06–13.84*
|
|
BMI (ref: normal weight)
|
18.38
|
2.24–150.63*
|
- The adjusted multivariable logistic regression analysis included 161 patients. Odds ratio (OR) and 95% confidence interval (CI) were calculated. *p value < 0.05 was considered statistically significant. TNFi tumour necrosis factor inhibitors, csDMARD conventional synthetic disease-modifying anti-rheumatic drug, BMI body mass index
